Alunbrig
Alunbrig ingredients
| Active ingredient | Strength |
|---|---|
| Brigatinib | 90 mg/1, 180 mg/1, 30 mg/1 |
What Alunbrig is used for
The FDA lists the approved uses on the official label (below). In the EU, brigatinib is approved as Alunbrig for:
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Alunbrig
- Generic name
- Brigatinib
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA208772
- On the US market since
- 2017
Official information
- Alunbrig prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Brigatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Alunbrig?
Alunbrig (Brigatinib) is a cancer medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Alunbrig?
Alunbrig contains Brigatinib (90 mg/1, 180 mg/1, 30 mg/1).
Is Alunbrig approved in Europe?
The same active substance is approved in the EU as Alunbrig.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA